DBV craters on FDA’s peanut allergy immunotherapy rejectionDBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led Share XDBV craters on FDA’s peanut allergy immunotherapy rejectionhttps://pharmaphorum.com/news/dbv-craters-on-fdas-peanut-allergy-immunotherapy-rejection/
FDA approves first ever peanut allergy therapy from AimmuneThe FDA has approved the first ever peanut allergy treatment, backing Aimmune’s Palforzia to reduce reactions in children. Share XFDA approves first ever peanut allergy therapy from Aimmunehttps://pharmaphorum.com/news/fda-approves-first-ever-peanut-allergy-therapy-from-aimmune/
FDA delays review of peanut allergy drug amid Trump shutdownOne of the first pharma victims of the current partial shutdown of the US government has emerged after Share XFDA delays review of peanut allergy drug amid Trump shutdownhttps://pharmaphorum.com/news/fda-delays-review-of-peanut-allergy-drug-amid-trump-shutdown/
